| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.2 | KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis |
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.11 | KE:352 | N/A, Neurodegeneration |
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.14 | KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells |
| AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive system disease | - | Caenorhabditis elegans | 0.12 | KE:1262 | Apoptosis |
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.17 | KE:1262 | Apoptosis |
| AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous system disease | Under Development | Human | 0.25 | KE:352 | N/A, Neurodegeneration |
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | 0.25 | KE:1262 | Apoptosis | |
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.11 | KE:1262 | Apoptosis |
| AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital nervous system abnormality; Nervous system disease | - | Homo sapiens, Mus musculus musculus, Rattus norvegicus | 0.14 | KE:1262 | Apoptosis |
| AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory system disease | - | 0.05 | KE:1262 | Apoptosis | |
| AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous system disease | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.14 | KE:352 | N/A, Neurodegeneration |
| AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory system disease | - | 0.09 | KE:1262 | Apoptosis | |
| AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | Mouse | 0.11 | KE:1262 | Apoptosis |
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | 0.09 | KE:1262 | Apoptosis | |
| AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | Mouse | 0.17 | KE:1262 | Apoptosis |
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.11 | KE:1183 | Decreased, Apoptosis (Epithelial Cells) | |
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.25 | KE:191 | Neuronal dysfunction |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.29 | KE:352 | N/A, Neurodegeneration |
| KE:1262 | Apoptosis | ||||||
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.11 | KE:1262 | Apoptosis |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:364 | Impaired development of, Reproductive organs | |
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.11 | KE:1262 | Apoptosis | |
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.17 | KE:1262 | Apoptosis |
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.17 | KE:2195 | Increase, CNS Neural cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.12 | KE:352 | N/A, Neurodegeneration |
| AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive system disease | - | 0.2 | KE:337 | N/A, Impairment of reproductive capacity | |
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.12 | KE:402 | Cognitive function, decreased |
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.17 | KE:330 | Decrease, Fertility |
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.11 | KE:402 | Cognitive function, decreased |
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.25 | KE:885 | Increase, Cancer |
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.17 | KE:1262 | Apoptosis |
| AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous system disease | - | Human | 0.14 | KE:1514 | Neurodegeneration |
| AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous system disease | - | 0.1 | KE:352 | N/A, Neurodegeneration | |
| AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | Rattus rattus, Mus musculus | 0.11 | KE:1193 | N/A, Breast Cancer |
| AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | 0.11 | KE:1193 | N/A, Breast Cancer | |
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive disorder | Under Review | Rattus norvegicus, Mouse, Humans | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Mouse, Monkey, Human | 0.12 | KE:402 | Cognitive function, decreased |
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.11 | KE:402 | Cognitive function, decreased |
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.2 | KE:885 | Increase, Cancer |
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.2 | KE:885 | Increase, Cancer |
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.17 | KE:885 | Increase, Cancer |
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 0.14 | KE:1064 | prepubertal increase, Estrogen receptor (ER) activity |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.